SPECIAL

Optimising the first-line treatment of patients with ROS1-rearranged non-small cell lung cancer

T. Feys

PARP inhibition as a new treatment modality in metastatic prostate cancer

T. Feys

Targeting RET-alterations in solid tumours

J. Blokken, T. Feys

Treatment sequencing in patients with advanced, BRAF-mutant melanoma

T. Feys, J. Blokken

Targeted therapy making its move in early-stage EGFR-mutant NSCLC

J. Blokken, T. Feys

The role of HER2-targeted therapy in metastatic gastrointestinal cancer: gastric cancer (and beyond)

T. Feys